AG Tumor­imaging
& Immunologie

Unsere Arbeitsgruppe befasst sich mit den drei Schwerpunkten:

  • Tumor Imaging
  • Radioonkologie
  • Biomarker und Tumor Immunologie

Tumor Imaging


Schwerpunkt Biomarker und Tumorimmunologie

Vicencio JM, Yellon DM, Sivaraman V, Das D, Boi-Doku C, Arjun S, Zheng Y, Riquelme JA, Kearney J, Sharma V, Multhoff G, Hall AR, Davidson SM. Plasma exosomes protect the myocardium from ischemia-reperfusion injury. J Am Coll Cardiol (JACC) 2015 Apr 21 65(15):1525-1536, 2015 (DOI 10.1007/s00262-015-1665-9) (15.3)

Specht HM, Ahrens N, Blankenstein C, Duell T, Fietkau R, Gaipl US, Günther C, Gunther S, Habl G, Hautmann H, Hautmann M, Huber RM, Molls M, Offner R, Rödel C, Rödel F, Schütz M, Combs SE, Multhoff G. Heat shock protein 70 (Hsp70) peptide activated NK cells for the treatment of patients with non-small cell lung carcinoma (NSCLC) after radiochemotherapy (RCTx) - from preclinical studies to a clinical phase II trial. Front Immunol. NK cell biology, Research Topic NK cell based immunotherapy. 2015 Apr 15 6:162: 1-9, 2015 (DOI 10.3389/fimmu.2015.00162) (4.0)

Gunther S, Ostheimer C, Stangl S, Specht HM, Mozes P, Jesinghaus M, Vordermark D, Combs SE, Peltz F, Jung MP, Multhoff G. Correlation of Hsp70 serum levels with gross tumor volume and composition of lymphocyte subpopulations in patients with squamous cell and adeno non-small cell lung cancer (NSCLC). Frontiers Immunol 6:556, 2015 (DOI 10.3389/fimmunol.2015.00556) (4)

Stangl S, Tontcheva N, Sievert W, Shevtsov M, Niu M, Schmid TE, Pigorsch S, Combs SE, Haller B, Balermpas P, Rödel F, Rödel C, Fokas E, Krause M, Linge A, Lohaus F, Baumann M, Tinhofer I, Budach V, Stuschke M, Grosu AL, Abdollahi A, Debus J, Belka C, Maihöfer C, Mönnich D, Zips D, Multhoff G. Heat shock protein 70 expression and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck (SCCHN) after radiochemotherapy: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology (DKTK-ROG) Int J Can 142(9):1911-1925, 2018 (DOI 10.1002/ijc.31213) (4)

Ostheimer C, Gunther S, Bache M, Vordermark D, Multhoff G. Dynamics of heat shock protein 70 (Hsp70) serum levels as a predictor of clinical response in non-small cell lung cancer (NSCLC) and correlation with the hypoxia-related marker osteopontin. Frontiers Immunol Inflammation Stress & Immunity 8:e1305, 2017 (DOI 10.3389/fimmu.2017.01305) (6.5)

Kokowski K, Stangl S, Seier S, Hildebrandt M, Vaupel P, Multhoff G. Radiochemotherapy combined with NK cell transfer folloed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study. Starhlenther Onkol 195:352, 2019

Shevtsov M, Pitkin E, Ischenko A, Stangl S, Khachatryan W, Galibin O, Edmond S, Lobinger D, Multhoff G. Ex vivo Hsp70 activated NK cells in combination with PD-1 inhibition significantly increase overall survival in preclinical models of glioblastoma and lung cancer. Front Immunol 10:e454, 2019 (7)

Multhoff G, Seier S, Stangl S, Sievert W, Shevtsov M, Werner C, Pockley AG, Blankenstein C, Hildebrandt M, Offner R, Ahrens N, Kokowski K, Hautmann M, Rödel C, Fietkau R, Lubgan D, Huber R, Hautmann H, Duell T, Molls M, Specht H, Haller B, Devecka M, Sauter A, Combs SE. Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial. Clin Cancer Res, doi: 10.1158/1078-0432.CCR-20-1141, 2020 (10.1)